- Current report filing (8-K)
November 02 2009 - 10:58AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): October 31, 2009
SHENGTAI
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-51312
|
|
54-2155579
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
Changda
Road East
Development
District, Changle County
Shandong, PRC 262400
(Address
of principal executive offices)
|
|
262400
(Zip
Code)
|
Registrant’s
telephone number, including area code:
011-86-536-218-2777
Copies to:
Benjamin
Tan, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway, 32 Floor
New York,
New York 10006
Phone:
(212) 930-9700
Fax:
(212) 930-9725
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
o
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications
pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02
Departure of
Directors or Principal Officers; Election of Directors; Appointment of Principal
Officers
On
October 31, 2009, we received notice from our director, Mr. Chris W. Wang
informing us that he would be resigning as director of the Company with effect
from October 31, 2009. Mr. Wang is also the Chairman of our
Compensation Committee. Mr. Wang cited insufficient time to commit to his
directorship due to his other work commitments as a reason for his
resignation. The Board of Directors approved his resignation on
October 31, 2009.
We
provided Mr. Wang with a copy of this disclosure before its filing with the SEC.
We requested that Mr. Wang provide us with a letter stating whether or not he
agrees with the above statements, and we received a letter from Mr. Wang stating
that he agrees with the above statements. A copy of this letter is
filed as an exhibit to this report.
Item
9.01
Financial Statements
and Exhibits
(d)
|
Exhibit No.
|
Description
|
|
|
|
|
99.1
|
Letter
dated October 31, 2009 from Chris Wang to the
Company.
|
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
SHENGTAI
PHARMACEUTICALS, INC.
|
|
|
|
|
Dated:
October 31, 2009
|
|
|
By:
/s/ Yiru
Shi
|
|
Name:
Yiru Shi
|
|
Title:
Chief Financial
Officer
|
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Sep 2023 to Sep 2024